Shared on20 Oct 25
Fair value Increased 1.54%

Narrative Update: Raia Drogasil Analyst Price Target Revision Analysts have raised their price target for Raia Drogasil from $21.58 to $21.91. They cite improved revenue growth projections and a marginally lower discount rate as key drivers of the upward revision.

Shared on27 Sep 25
Fair value Decreased 2.18%

Raia Drogasil’s slight price target reduction to R$21.58 primarily reflects a modest decrease in its expected future P/E ratio despite a marginal improvement in net profit margin. What's in the News Board approved payment of BRL 131.8 million in interest on equity, equating to BRL 0.076940867 per share, to be paid by December 5, 2025; no monetary restatement applicable.

Shared on12 Sep 25
Fair value Increased 2.41%

The slight upward revisions in both Raia Drogasil’s expected revenue growth and future P/E reflect improved growth prospects, leading analysts to raise their consensus price target from R$21.54 to R$22.06. What's in the News Board approved payment of BRL 131.8 million in interest on equity, equivalent to BRL 0.076940867 per share, to be paid by December 5, 2025; no monetary restatement applies.

Shared on28 Aug 25
Fair value Increased 3.69%

Raia Drogasil's consensus price target has increased to R$21.21, with both its future P/E and discount rate remaining largely stable, indicating steady valuation assumptions amid the upward fair value revision. What's in the News Board approved payment of BRL 131.8 million in interest on equity, equivalent to BRL 0.076940867 per share, to be paid by December 5, 2025.